Literature DB >> 14673951

Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis.

J Rubin1, L W K Chung, X Fan, L Zhu, T C Murphy, M S Nanes, C J Rosen.   

Abstract

BACKGROUND: Prostate cancer (PC) has a propensity to metastasize to the skeleton, inducing an osteoblastic response in the host. Recent epidemiological studies have suggested that circulating IGF-I may be important for both the pathogenesis and dissemination of PC. We have postulated that tumor secreted IGF-I in conjunction with endogenous IGF-I contributes to the osteoblastic phenotype characteristic of metastatic PC.
METHODS: To test this thesis we studied the established LNCaP PC progression model consisting of three genetically related human PC cell lines.
RESULTS: Using RIA, we found serum-free conditioned media (CM) of LNCaP and C4-2 had no measurable IGF-I, whereas IGF-I was easily detected in CM from C4-2B cells at 24 hr (i.e., 1.8 +/- 0.53 ng/mg cell protein). Real-time PCR of IGF-I mRNA showed that C4-2B expressed 100-fold more IGF-I mRNA than LNCaP cells. In addition, C4-2B expression of IGF-I mRNA was substantially increased in the presence of exogenous IGF-I to nearly twofold. While IGFBP-3 and IGFBP-1 were not detectable in the CM of any PC line, all cells secreted IGFBP-2. C4-2B cells produced 40% more IGFBP-2 than LNCaP or C4-2 cells (C4-2B at 167 +/- 43 ng/mg cell protein). RANKL, a product of bone stromal cells, was also differentially expressed: LNCaP had threefold higher RANKL mRNA compared to C4-2 and C4-2B and at least equivalent protein expression.
CONCLUSIONS: Our results suggest that PC cells that have metastasized to bone have an upregulated IGF-I regulatory system. This suggests an activated IGF-I axis contributes to the host-PC interaction in promoting osteoblastic metastases. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14673951     DOI: 10.1002/pros.10299

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  8 in total

1.  Androgen mediated translational and postranslational regulation of IGFBP-2 in androgen-sensitive LNCaP human prostate cancer cells.

Authors:  David J Degraff; Adam A Aguiar; Qian Chen; Lisa K Adams; B Jill Williams; Robert A Sikes
Journal:  Am J Transl Res       Date:  2010-03-06       Impact factor: 4.060

Review 2.  Steps in prostate cancer progression that lead to bone metastasis.

Authors:  Jung-Kang Jin; Farshid Dayyani; Gary E Gallick
Journal:  Int J Cancer       Date:  2011-03-28       Impact factor: 7.396

3.  A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.

Authors:  Maha Hussain; Dana Rathkopf; Glenn Liu; Andrew Armstrong; Wm Kevin Kelly; Anna Ferrari; John Hainsworth; Adarsh Joshi; Rebecca R Hozak; Ling Yang; Jonathan D Schwartz; Celestia S Higano
Journal:  Eur J Cancer       Date:  2015-06-13       Impact factor: 9.162

4.  Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.

Authors:  David J Degraff; Adam A Aguiar; Robert A Sikes
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

5.  Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion.

Authors:  Fraser Conrad; Xiaodong Zhu; Xin Zhang; Robert J Chalkley; Alma L Burlingame; James D Marks; Bin Liu
Journal:  J Mol Med (Berl)       Date:  2009-02-14       Impact factor: 4.599

6.  Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth.

Authors:  R Daniel Bonfil; Zhong Dong; J Carlos Trindade Filho; Aaron Sabbota; Pamela Osenkowski; Sanaa Nabha; Hamilto Yamamoto; Sreenivasa R Chinni; Huiren Zhao; Shahriar Mobashery; Robert L Vessella; Rafael Fridman; Michael L Cher
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

Review 7.  Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies.

Authors:  Tilman Todenhöfer; Arnulf Stenzl; Lorenz C Hofbauer; Tilman D Rachner
Journal:  Int J Endocrinol       Date:  2015-01-31       Impact factor: 3.257

8.  Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases.

Authors:  Colm Morrissey; Paul L Kostenuik; Lisha G Brown; Robert L Vessella; Eva Corey
Journal:  BMC Cancer       Date:  2007-08-03       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.